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Summary
Background: Early results from the use of neuromodulation by percutaneous electrical nerve stimulation for the management of trigeminal-mediated
headshaking in horses were promising but lacked sufficient case numbers and long-term follow-up. The neuromodulatory procedure has since been
established as EquiPENSTM.
Objectives: The aim of this study was to report long-term results from a larger number of cases and to investigate for predictors of outcome.
Study design: Prospective case series using international, multi-centre data.
Methods: Eligible cases were horses with a veterinary diagnosis of trigeminal-mediated headshaking, which received EquiPENSTM neuromodulation at
trained centres between August 2013 and November 2017. The standard protocol was an initial three-procedure course, with additional procedures
should a horse go into remission but then relapse. Data collected included signalment, history, diagnostic tests performed, details of any complications,
whether horses had gone into remission and the length of remission.
Results: Results were obtained from 168 horses, with 530 procedures. The complication rate was 8.8% of procedures. In all but one case,
complications were mild and transient, without self-trauma. Remission of headshaking following the initial course occurred in 53% (72/136) of horses.
Median length of time recorded in remission was 9.5 weeks (range 2 days to 156 weeks ongoing). Where signs recurred, most horses went back into
remission following additional procedures, usually for longer than from the previous procedure. No predictors for outcome were determined.
Main limitations: No placebo or control group, owner-assessed results.
Conclusions: EquiPENSTM neuromodulation can be an effective and safe treatment for the management of trigeminal-mediated headshaking in some
horses. An increased understanding of neuromodulation could help optimise the technique. Advances in treatment for trigeminal-mediated
headshaking will remain limited until there is a greater understanding of the aetiopathogenesis of the condition.
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Introduction
Trigeminal-mediated headshaking is an idiopathic neuropathic facial pain
condition of the horse. The condition can have important welfare
implications [1]. It carries a poor prognosis, with published treatments
lacking consistent efficacy, and in some instances, safety and practical
application [2–5]. The use of a nose-net improves clinical signs by 70% or
greater in one-third of horses [6]. A nose-net is non-invasive and cheap and
is usually the first-line of treatment but its use in competition is not
accepted by all equestrian organisations. Medical treatment with
carbamazepine and/or cyproheptadine [2,7] can be effective in some
individuals. However, in general, results are inconsistent, and the use of
these pharmaceuticals can be expensive, associated with side effects of
drowsiness and would not usually be permitted in competition. The
surgical placement of platinum coils within the infraorbital canal was
reported to have a 49% remission rate [5] but resulted in adverse effects of
enough severity as to result in euthanasia in 4/58 horses.
Advances in the treatment for trigeminal-mediated headshaking will
remain limited until the aetiopathogenesis of the condition is understood.
The most recent advance was that the trigeminal nerve of affected horses
is sensitised, having a reduced threshold for activation, which is thought to
result in neuropathic pain [8]. The nerve is functionally abnormal but
appears to be structurally normal [9] which could mean that the
sensitisation is reversible. Following on from this, percutaneous electrical
nerve stimulation, a repeatable, minimally invasive neuromodulatory
therapy with some application for the management of neuropathic pain in
people, was trialled in seven horses [10]. All horses tolerated the procedure
well. Three horses developed a haematoma at the site on one occasion and
two had increased clinical signs suspected to be due to a transient neuritis,
for up to 3 days following one of the procedures. All horses underwent a
minimum of three procedures, with two horses having four procedures.
Following their last procedure, remission, classed as ridden work at their
previous level, was obtained in five horses, with a median remission time of
15.5 weeks from the third procedure and 20 weeks from the fourth. These
early results were promising for management of the condition but lacked
sufficient case numbers and long-term follow-up. Following this, the use of
electroacupuncture, which uses a different electrical algorithm, equipment
and technique, gave positive results in a small number of suspected
trigeminal-mediated headshakers [11].
The percutaneous electrical neuromodulatory procedure has since been
established as EquiPENSTM and various centres across the UK and Europe
have been trained by the first author in the technique, using the same
equipmenta, ensuring consistency. The aim of this study is to report long-
term results for treatment with EquiPENSTM and to identify any predictors
for outcome from a larger number of cases, using international, multi-
centre data.
Materials and methods
Eligible cases were horses with a veterinary diagnosis of trigeminal-
mediated headshaking, which received EquiPENSTM neuromodulation at
1Details of collaborators are listed in Supplementary Item 1.
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trained centres between August 2013 and November 2017. Centres were
issued with guidelines for reaching a diagnosis of trigeminal-mediated
headshaking. These are detailed in Supplementary Item 2. Horses could
have previously received, but responded insufficiently to, other treatments
for headshaking, but were not receiving any other treatment at the time of
enrolment. In order to assess response to treatment, horses were in
ridden or lunge work prior to the onset of clinical signs of headshaking.
EquiPENSTM neuromodulation was performed as described previously [10].
The protocol was for each horse to receive an initial course of three
procedures. The second procedure was performed 3–7 days after the first
procedure, and the third procedure was performed 10–14 days after the
second procedure. Intervals were extended if a horse went into remission
after a procedure, until it relapsed. If the horse went into remission after
three procedures but then relapsed, additional procedures could be
performed.
A standard recording form was available to each centre for prospective
collection of data regarding each horse’s signalment, history and the
diagnostic tests they performed. The information requested included
whether signs were known to be spring/summer seasonal only or present
all year round. Seasonality of signs was recorded as unknown in those
cases which were reported to have been affected for less than a year. The
diagnosis of trigeminal-mediated headshaking was made by exclusion. If
during investigation abnormalities were detected, these were judged to
not be clinically relevant, sometimes after treatment with no response.
Examples would include sharp dental arcades and iris cyst.
Centres were also asked to record the following information for each
EquiPENSTM procedure performed for each case: the date of the procedure;
whether any complications were experienced during or after the
procedure and the nature of those complications; whether the horse went
into remission; and if so, for how long. Remission was defined as return to
ridden exercise (or if not trained, lunge exercise) at, or above, the level of
performance prior to the onset of clinical signs, within 3 weeks from the
last procedure. This was an assessment made by the owner. Follow-up on
each case was obtained by the centre responsible for that case by
telephone questionnaire (Supplementary Item 3). The longest-term
available follow-up was used in this study. Where horses had been initially
classified as going into remission with an initial follow-up performed prior
to March 2016, follow-up was repeated between July and November 2017.
Where horses could no longer be classified as being in remission, whether
this was due to recurrence of headshaking signs or because horses could
no longer be assessed as they were out of ridden work for other reasons,
was recorded. Otherwise, remission was recorded as being on-going at the
time of follow-up.
Data analysis
Statistical analysis was performed using the survival and survminer
packages for the R statistical program (Version 3.4.4)b and R Studio
(Version 1.1.423)b running on Ubuntu 17.10c. Censored survival objects
were created using the Surv function of the survival package and Kaplan
Meier plots created using the survfit and ggsurvplot functions. Probabilities
for differences in length of remission after third or final treatment
dependent on response to first or second treatments were calculated
using log-rank methods. Cox proportional hazards for presence of and
differences in length of remission dependent on management, centre and
history prior to treatment were calculated using the coxph function.
Variables tested were: the time for which the horse had been affected with
clinical signs prior to presentation; whether use of a nosenet had, judged
by the owner, no effect on clinical signs, insufficient effect or aggravated
clinical signs; whether diagnostic local anaesthesia had been performed,
the location of that anaesthesia and the result; seasonality.
Results
Population statistics
There were 168 horses fitting the inclusion criteria. The median age at
presentation was 9 years (range 2–21 years, n = 163, 5 not recorded). The
most common groups of breeds were sports horses (49/160, 31% 8 not
recorded) and warmbloods (42/160, 26%). Age ranges appeared evenly
distributed across the breeds (Supplementary Item 4). There were 120/165
(73%) geldings, 42/165 (25%) mares and 3/165 (2%) stallions. The sex of 3
horses was not recorded. Procedures were performed at 13 trained
centres across the UK and Europe. On occasion, diagnostics and the first
one or two procedures were performed at one centre, with other
procedures performed at a different centre. In these instances, the first
centre only was attributed the case. The distribution of cases across the
centres is displayed in Supplementary Item 5.
Most horses (94/166, 57%, 2 not recorded) were used for general riding.
Distribution of use is displayed in Supplementary Item 6.
Prior treatment
Nose-nets had been trialled for treatment in 128 horses and it was
reported by the owner to have no, or insufficient, effect in 109/128 (84%)
cases and worsen clinical signs in 16/128 (12%) cases. Three horses whose
clinical signs were alleviated by use of a nose-net were presented for
treatment because they were unable to compete in their discipline with a
nose-net.
Distribution of the main other attempted treatments are shown in
Supplementary Item 7. None of these treatments were reported by the
owners to have been effective or sufficiently effective. Less commonly
used, attempted but failed, treatments reported by owners are detailed in
Supplementary Item 8.
Diagnosis
All horses were diagnosed with trigeminal-mediated headshaking by
veterinary surgeons. European or American board-certified specialists were
responsible for case management at 9/13 centres. The median length of
time for which horses were affected prior to presentation was 4 months
(range 0.5–84 months, n = 153, 15 not recorded). There were 21/158 (13%
10 not recorded) horses known to be Spring/Summer seasonally affected
and 62/158 (39%) horses known to be affected all year round. Seasonality
was unknown i.e. horses having been affected for less than a year, in 75/
158 cases (48%).
The diagnostic techniques performed included computed tomography of
the head in 124/168 (85%) cases (21 not performed, 23 not recorded).
Diagnostic local anaesthesia was performed bilaterally at the caudal point
of the infraorbital canal in 51 cases, giving a positive result in 35/51 (68%).
Bilateral diagnostic local anaesthesia of the infraorbital nerve at the level of
the infraorbital foramen was performed in a further three cases, giving a
positive result in two cases. Diagnostic local analgesia was not performed
in 79/133 (59%) cases).
Procedure information
A total of 530 procedures were performed. Of the 168 horses which
began the initial three-procedure course, 156 horses had completed the
course at the time of follow up. Details regarding non-completion are in
Table 1.
If horses had gone into remission following the initial three-procedure
course, they were eligible for an additional procedure should signs return.
Of these eligible horses, 26 underwent a fourth procedure, 11 underwent a
fifth procedure and 4 underwent a sixth procedure.
The median interval between the first and second procedures was
6 days (range 3–36 days due to long remission from the first procedure,
n = 133, interval not recorded in 32 horses, three horses did not continue
to a second procedure or had not done so by the time of follow-up
(Table 1) and the second and third was 14 days (range 4–165 days due to
long remission from the second procedure, n = 125, interval not recorded
in 31 horses, 9 horses did not continue to a third procedure or had not
done so by the time of follow-up (Table 1).
Complications
Complications were reported in 47/530 procedures (8.8%, Table 2). In all
but one case, complications were transient. Of these, worsening of signs
presumed to be secondary to neuritis was the most frequent complication
occurring in 18/530 (3.4% procedures). No self-trauma was reported. All but
one horse’s signs returned at least to pre-treatment baseline in a few days
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and this occurred more rapidly if dexamethasone was administered
intravenously at 0.1 mg/kg. One horse, treated soon after the onset of
headshaking, showed a worsening of signs after each of two procedures.
The horse’s compliance was also poor, so it was decided not to perform
the third procedure and that horse’s clinical signs continued to progress. It
is unclear whether this progression was a direct result of the
neuromodulatory therapy, or the natural disease course in this horse.
Suspected neuritis was reported more than once over the treatment
course in four cases, which accounted for 9/18 (50%) of episodes. This was
reported on two occasions in three cases; in one case with the first and
third procedures and in the others with the first and second. One of these
is the horse detailed above which had also complied poorly with the
procedures, so a third procedure was not attempted. In the other case,
dexamethasone was given prior to the third procedure and no subsequent
neuritis was observed. Suspected neuritis occurred after all three
procedures in one case.
Success rates
The proportion of horses going into remission following the initial three-
procedure course was 53% (72/136 with follow-up data which includes two
horses which remained in remission after two procedures and did not
complete the third, 64/136 were non-responders, 20/156 were lost to
follow-up or could not be evaluated due to being out of work because of
other conditions). The median duration of remission was 9.5 weeks (range
2 days to 156 weeks and ongoing). This calculation of the duration of
remission included not only the length of time until signs returned (36/72,
50%) but also the time to follow-up for those still in remission at the end of
the study (33/72, 46%). There were a small number of horses (3/72, 4%)
which, having gone into remission were then out of work for reasons other
than headshaking. For these horses, the duration of remission was taken to
be until the last date the horses could be assessed i.e. when still in ridden
work. Figure 1 displays how remission was sustained over time. At
56 weeks following the third procedure, 15% of cases remained in
remission and these then remained in on-going remission at the last follow
up at 156 weeks, with no further horses relapsing.
Within the initial three-procedure course, 35% (46/130) of horses went
into remission after the first procedure (84/130 not in remission, 38/168 not
recorded) with a median length of remission of 3 days (range, 1–14 days)
before relapsing prior to the second procedure. Following the second
procedure, 43% (60/137) of horses went into remission (77/137 not in
remission, 28/165 not recorded) before relapsing prior to the third
procedure. The median length of remission was 2 weeks (range, 2 days to
61 weeks) before relapse.
A Cox proportional hazards regression model was performed to assess
for significant predictors of remission after the initial three-procedure
course. Nerve blocks, centre and seasonality were all non-significant
(P>=0.15) and are displayed in Table 3. However, horses were significantly
(P<0.001) more likely to go into remission at the end of the first three-
procedure course if they went into remission after the first procedure and
second procedures, but horses could still respond if the first procedure
was unsuccessful.
There were 26 horses which, following recurrence after remission from
the initial course, received a fourth procedure. Of these initial responders,
69% (18/26) went back into remission. There were 32% of horses still in
remission 12 weeks after the fourth procedure and these remained in on-
going remission with up to 140 weeks’ follow-up.
There were 11 horses which received a fifth procedure. Of these, 82% (9/
11) went back into remission. There were 30% of these horses still in
TABLE 1: Reasons for horses enrolled in the study to have not completed the initial three-procedure course at the time of follow-up
Reason for non-completion
Procedure
number
Number of
horses
In
remission
Withdrawn due to developing other
medical condition
Horse
compliance
Owner
compliance
Course not yet completed at
time of follow up Unknown
1 168
2 165 2 1
3 156 2 1 1 1 3 1
TABLE 2: Complications recorded and numbers affected for each procedure
Complication
Procedure number Suspected neuritis Horse compliance Haematoma Dermatitis Catheter complication Colic
1 7 2 6 4 3 1
2 6 1 4 2 0 0
3 5 0 5 0 0 0
4 0 0 0 0 0 0
5 0 0 1 0 0 0
6 0 0 0 0 0 0
0 50
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Fig 1: Kaplan-Meier survival plot demonstrating the proportion of horses entering
remission at the end of the initial three-procedure course and the maintenance
of remission over time. The dotted lines are 95% confidence intervals.
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remission 14 weeks after the fifth procedure and these horses remained in
on-going remission with up to 140 weeks’ follow-up. Figure 2
demonstrates the proportion of horses in remission after the last
procedure they received and the maintenance of remission over time.
There were four horses which went on to have a sixth procedure following
recurrence of signs after a fifth procedure. Two went back into remission,
which was ongoing at 28 and 56 weeks after this sixth procedure.
Discussion
This study demonstrates that EquiPENSTM neuromodulation can be an
effective and safe treatment for the management of trigeminal-mediated
headshaking in some horses. The data suggest that approximately 50% of
cases will respond to the initial three-procedure course. Crucial, however,
is whether remission is sustained and if not, how long until signs can be
expected to recur and whether further treatment will result in remission
again. Our results suggest that should a horse remain in remission for
longer than 56 weeks from the initial course, the remission might last for
years. However, for most horses, it can be expected that remission will be
shorter. The median length of remission was 9.5 weeks. However, it
should be noted that almost half of the cases were still in remission at the
time of follow-up, so a longer study would be likely to show a longer
median remission time. When signs recur, most but not all, horses can be
expected to return to remission following additional procedures. This
return to remission was usually but not always longer-lasting than from
after the previous procedure.
There was wide individual variation in how horses responded and no
predictors of response were identified. Whilst horses were more likely
to go into remission at the end of the initial three-procedure course if
they had gone into remission following the first and second
procedures, this was not exclusively the case. The only way to know if
a horse will respond is to attempt treatment. Where horses responded
to the initial course it was not possible to predict length of remission.
Although most horses which responded but then relapsed did respond
again to additional procedures, this was not the case for all. Even in a
successful case, this uncertainty would impact on a horse’s re-sale
value.
The numbers of horses going into remission increased with each
subsequent treatment within the initial course. Horses were more likely to
go into remission at the end of the course if they had responded during
the course. This suggests a minimum of three procedures should be
undertaken. There may be benefit in continuing to pursue treatment in
horses which have not responded to the third procedure, but with
reducing odds of success. It is, therefore, the authors’ recommendation
that the protocol of performing an initial three-procedure course be
continued with a fourth procedure only being offered to responders which
have then relapsed.
A further advantage of EquiPENSTM is the short competition detection
time for pharmaceuticals used during the procedure, namely sedation
and local anaesthetic. This allowed several horses in this study to
compete at a high level whilst their clinical signs were managed with
EquiPENSTM.
TABLE 3: Results of Cox proportional hazards regression model for predictors from history on outcome of remission or not after the initial
three procedure course
Variable Coef Exp (coef) Se (coef) z P
Duration of clinical signs prior to presentation 2.322e02 9.770e01 1.700e02 1.366 0.2
Caudal infra-orbital nerve block, negative result 4.373e01 1.549e+00 4.936e01 0.886 0.4
Rostral in infra-orbital nerve block, negative result 1.723e+01 3.288e08 4.143e+03 0.004 >0.9
Caudal infra-orbital nerve block, positive result 2.777e01 1.320e+00 3.469e01 0.800 0.4
Rostral in infra-orbital nerve block, positive result 1.906e+00 6.724e+00 1.139e+00 1.673 0.09
Nosenet – no response 1.361e+00 2.565e01 1.149e+00 1.185 0.2
Nosenet – insufficient response 1.551e+00 2.121e01 1.183e+00 1.311 0.2
Nosenet – worse signs 1.423e+00 2.409e01 1.219e+00 1.167 0.2
Seasonal signs 8.198e02 9.213e01 5.636e01 0.145 0.9
Seasonality unknown 7.643e02 9.264e01 3.500e01 0.218 0.8
Centre 2 8.944e01 4.088e01 1.047e+00 0.854 0.4
Centre 3 8.620e01 2.368e+00 8.560e01 1.007 0.3
Centre 4 4.572e03 9.954e01 5.147e01 0.009 >0.9
Centre 5 1.323e01 1.141e+00 6.398e01 0.207 0.8
Centre 6 7.549e02 1.078e+00 1.043e+00 0.072 0.9
Centre 7 NA NA 0.000e+00 NA NA
Centre 8 NA NA 0.000e+00 NA NA
Centre 9 2.912e01 1.338e+00 6.403e01 0.455 0.6
Centre 10 1.007e01 1.106e+00 1.062e+00 0.095 0.9
Centre 11 1.023e+00 3.596e01 7.896e01 1.295 0.2
Centre 12 1.142e+00 3.132e+00 7.822e01 1.460 0.1
Centre 13 2.298e01 1.258e+00 6.207e01 0.370 0.7
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Fig 2: Kaplan-Meier survival plot demonstrating the proportion of horses entering
remission after their last procedure and the maintenance of remission over time.
The dotted lines are 95% confidence intervals.
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Studies of headshaking are at risk of a placebo effect and false positive
results due to spontaneous remission. There are two studies on
headshaking treatments which were designed in such a way as to be able
to quantify the placebo effect on owners of treatments for this condition
[12,13]. The study by Pickles et al. [12] investigated an effect of a
gonadotrophin-releasing hormone vaccine in trigeminal-mediated
headshakers. One-third of owners reported a subjective improvement in
headshaking signs, but no real improvement was detected when
considering results of serial scoring of signs on a visual analogue scale
made by the same owners. The study by Talbot et al. [13] was a double-
blinded placebo-controlled trial of a commercially available feed
supplement for headshaking. Videos taken at set time-points within the
study were assessed by veterinary surgeons with no significant difference
found across the study, contrasting with the owners’ positive subjective
impression of effect on headshaking signs of both the supplement and the
placebo. Ideally, our study would have included a placebo or control
group. The data from our study suggests that for a control to be valid, the
horse should be monitored for clinical signs for 1 year. During this year, no
other treatments could be administered and the horse not euthanased. It
would not be ethical to enrol horses into this study to leave them without
treatment for a painful condition. A sham treatment course could be used,
inserting the probes under sedation but not performing electrical
stimulation. The sham treatment would have to be performed first and the
real treatment 6 weeks later. Government ethical approval would have to
be obtained for this study and it would be unlikely to be obtained, given
the considerable time-period where no other treatment could be
administered if horses were showing clinical signs of pain. The results of
this study, relying on owner reports at follow-up, must be considered in
the light of a lack of a placebo or control group. However, steps were
taken in study design to reduce a placebo effect. All horses were showing
clinical signs at the time of treatment. Remission was taken as return to
ridden exercise at the previous level, in all but one case which was not yet
in ridden work and so was assessed on the lunge, within 3 weeks of the
last procedure.
The practical nature of the definition given to remission was chosen as
being less likely to result in a false positive result than the owners’
subjective interpretation of improvement in signs [12,13].
There is a risk of false positive results, with headshaking signs having
resolved due to a change of season, or to spontaneous resolution of the
condition. To reduce this risk, signs had to resolve within 3 weeks of the
last procedure for that resolution to be attributed to the neuromodulation.
There was no effect of seasonality on chances of, or length of, remission.
Spontaneous remission, considered to be where signs resolved for 1 year
or greater, to differentiate from seasonal remission, is reported from an
owner survey to occur in 5% of headshakers [3]. The median length of time
for which horses were affected prior to presentation was 4 months, range
0.5-84 months. It would seem unlikely that the 50% of horses going into
remission within 3 weeks of neuromodulation would all have recovered
spontaneously.
It is possible that some of the horses in this study were mis-diagnosed,
which would confound results. The diagnosis of trigeminal-mediated
headshaking is currently one of exclusion, making mis-diagnosis more likely
than for a condition where there is a specific test. Furthermore, the
diagnoses were made by several different veterinary surgeons at different
centres and in different countries. All centres were provided with
guidelines for reaching a diagnosis. These guidelines had to accommodate
some variation between centres, for example computed tomography of
the head was not available at the time in all the countries. It may be
possible in the future to further develop a technique measuring
somatosensory evoked potentials as a definitive test for trigeminal nerve
sensitisation, which alongside the guidelines issued to centres, would
improve accuracy of diagnosis.
Complication rates were low, and in all but one case, all side-effects
were transient. This is of importance for a technique which must be
repeated and has far from a guarantee of success. Where horses
exhibited signs consistent with suspected neuritis, there was a strong
tendency for these signs to occur again following the next procedure. In
these cases, there may be some merit to considering administration of
dexamethasone prior to the next procedure. This may reduce the risk of
recurrence of suspected neuritis, although this is based on only one
horse. There may also be merit to local administration of corticosteroid,
although the authors have not trialled this yet. Even in horses where
dexamethasone was not administered for suspected neuritis, signs did not
result in self-trauma and resolved in a few days in all but one case, so the
risk to benefit ratio of corticosteroid administration should be considered
on an individual basis.
Advances in treatment for trigeminal-mediated headshaking will remain
limited until the aetiopathogenesis of the condition is understood. It is
certainly possible that there is more than one cause with the same clinical
manifestation, leading to different response rates to treatment. It is
recognised in human medicine that response to treatment for neuropathic
pain varies amongst individuals, even with the same diagnosis [14].
Therefore, even if all trigeminal-mediated headshakers have the same
underlying condition, response to the same treatment may vary. Also, the
mechanism of action of any neuromodulatory therapy is not well
understood. There is a need for research into neurophysiology pre- and
post-neuromodulation in any species. The lack of knowledge in this area
limits our ability to determine whether adaptations of the EquiPENSTM
technique could lead to remission in non-responders and longer remission
times in responders. It also limits our ability to compare the technique to
electroacupuncture [11], leaving the only way to make a comparison being
to compare the use of a uniform electroacupuncture technique over a
similar number of appropriately diagnosed horses.
In conclusion, based on these results, we recommend that at
present, EquiPENSTM neuromodulation be considered for the
management of trigeminal-mediated headshaking in horses where a
nose-net is unsuitable. Further advances in the understanding of the
aetiopathogenesis of trigeminal-mediated headshaking are vital for there
to be real progress in treating the condition. In the shorter term, a
greater understanding of neuromodulation could aid refinement of the
EquiPENSTM technique.
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